Clinical trials: Renal Carcinoma
Kidney Cancer
Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00445757
- Testing
- conventional surgery, stereotactic radiosurgery
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Esophageal Cancer, Kidney Cancer
GI Organ Tracking Via Balloon Applicators
The hypothesis of this study is that an occlusion balloon catheter placed in the stomach via an oral or nasogastric route will be safe and permit tracking of the stomach during radiation therapy.
- Conditions
- Esophageal Cancer, Kidney Cancer, Larynx Cancer, Liver Cancer
- Trial name
- NCT05471401
- Testing
- Balloon-tipped catheter
- Sponsor
- Washington University School of Medicine
Renal Cell Carcinoma (Kidney Cancer)
Patient Reported Outcomes and Different Renal Artery Clamping Techniques During Robot Assisted Kidney Resection
The target population for this study consists of all patients undergoing kidney surgery at Haukeland University Hospital, Norway, with the primary focus being patients undergoing robot-assisted partial nephrectomy.
- Trial name
- RAPTOR (NCT07853001)
- Testing
- Standard clamping strategy, Early declamping strategy
- Where
- Norway
- Volunteers
- 130 people
- Sponsor
- Bjarte Almas
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
Metastatic Cancer, Metastatic Melanoma
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients metastatic cancer that involves taking white blood cells from the patient, growing them in the laboratory…
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Renal Cancer
- Trial name
- NCT01218867
- Testing
- Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Vaccine Therapy in Treating Patients With Kidney Cancer
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with…
- Trial name
- NCT00096629
- Testing
- human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Cancer
International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors
Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible.
- Trial name
- i-RECORd (NCT05363657)
- Testing
- Partial Nephrectomy (PN), Radical Nephrectomy (RN), Ablation therapy (AT)
- Where
- 37 sites in United States, Austria and 11 more
- Volunteers
- 10,000 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Renal Cell Carcinoma
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo.
- Trial name
- COSMIC-313 (NCT03937219)
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 159 sites in United States, Argentina and 23 more
- Volunteers
- 855 people
- Sponsor
- Exelixis
Metastatic Renal Cell Carcinoma
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy…
- Trial name
- NCT01265901
- Testing
- Sunitinib, GM-CSF, Cyclophosphamide
- Where
- 105 sites in United States, France and 9 more
- Volunteers
- 339 people
- Sponsor
- Immatics Biotechnologies GmbH
Solid Tumor, Lymphoma
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors.
- Trial name
- NCT00413075
- Testing
- oral belinostat
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 121 people
- Sponsor
- Valerio Therapeutics
Kidney Cancer
Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)
RATIONALE: Radiofrequency interstitial tissue ablation may kill tumor cells by heating tumors to several degrees above body temperature.
- Trial name
- NCT00019955
- Testing
- laparoscopic surgery, radiofrequency ablation, thermal ablation therapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Breast Carcinoma, Kidney Carcinoma
Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
This study aims to develop objective tools for assessing perceived pain severity in cancer patients and survivors, evaluate the sustained effectiveness of non-pharmacological interventions such as virtual reality in reducing pain…
- Conditions
- Breast Carcinoma, Kidney Carcinoma, Carcinoma
- Trial name
- NCT06456411
- Testing
- Functional Near-Infrared Spectroscopy, Questionnaire Administration, Virtual Technology Intervention
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Wilms Tumor, Relapse
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence
Wilms' tumour staging and grading are used to give an idea about the prognosis. Advanced staging, diffuse anaplasia, predominant blastemal elements and lymph node invasion are indicators of poor prognosis.
- Conditions
- Wilms Tumor, Relapse, Death
- Trial name
- NCT04758455
- Testing
- P53, Ki67 and Cyclin A IHC.
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Mansoura University
Renal Cell Carcinoma, Neoplasm Metastases
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
The purpose of this research study is to determine if the combination of sunitinib and gemcitabine is effective in treating patients with metastatic renal cell carcinoma. The safety of this combination will also be studied.
- Trial name
- NCT00556049
- Testing
- Gemcitabine, Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Kidney Neoplasms
[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment
Background: The experimental contrast agent [18]F-Fluciclatide is being tested for cancer treatment imaging studies. It is designed to show tumors in which new blood vessels are growing.
- Trial name
- NCT01633255
- Testing
- 18F-Fluciclatide
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease progression of patients with metastatic Renal Cell…
- Trial name
- NCT00522249
- Testing
- Pegylated Alfa Interferon, sunitinib, erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Cancer, Kidney Neoplasms
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or…
- Conditions
- Breast Cancer, Kidney Neoplasms, Liver Neoplasms
- Trial name
- NCT07225114
- Testing
- contrast agent perflutren lipid, Ultrasound Imaging
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Radiation Therapy, Targeted Therapy
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
This is a prospective, single-center clinical trial designed to evaluate the safety and efficacy of combining stereotactic ablative body radiotherapy (SABR) with the targeted therapy Axitinib and the immunotherapy Toripalimab in…
- Conditions
- Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic
- Trial name
- NCT06889649
- Testing
- Stereotactic Ablative Body Radiotherapy (SABR), TORIPALIMAB INJECTION(JS001 ), Axitinib (VEGF-TKI)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Partial Nephrectomy, Kidney Cancer
Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy
After partial nephrectomy, kidney function decreases by about 10% overall and by about 20% in the operated kidney. This is primarily due to the loss of healthy parenchymal volume during resection of the tumor.
- Conditions
- Partial Nephrectomy, Kidney Cancer, Renal Function Aggravated
- Trial name
- NCT03323021
- Testing
- Dehydrated human amnion/chorion membrane, Standard of Care
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- MiMedx Group, Inc.
Carcinoma, Renal Cell
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
There are two primary aims in the study: 1) to determine the tolerability and feasibility of combination hypofractionated radiation therapy and PD-1 inhibition with nivolumab, and 2) to determine the ability of hypofractionated…
- Trial name
- NCT02962804
- Testing
- Nivolumab, Radiation
- Where
- United States
- Sponsor
- University of Kansas Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.